Literature DB >> 35891762

Investigation of the Effect of Atorvastatin on Skeletal Muscles in Male Rats and the Involved Mechanisms.

K M Hassani1.   

Abstract

It has been approved that atrovastatin is a preferred treatment for hyperlipidemia. One of the atrovastatin drawbacks would be the detrimental effects on skeletal muscles. Therefore, the current study was designed to evaluate all the skeletal muscles alteration in rats' after administration of atrovastatin and identification the mechanisms involved in these structural alterations in the skeletal muscles. A total of 12 healthy adult male rats (Rattus norvegicus) were randomly divided into two groups (n=6). The control group (G1) included rats that received distilled water as the placebo, and the treatment group (G2) included animals that were treated with atorvastatin (80 mg/kg/day) dissolved in distilled water and administrated by a gastric tube for eight weeks. At the end of the experiment, trapezius and vastus medialis muscle tissues were sampled and fixed with 10% formalin for histopathological studies. Atorvastatin administration gave rise to morphological changes in the skeletal muscle fibers and the nerve fibers, including atrophied myofibers, infarction, irregular arrangement of myonuclei, disappearance of nuclei from their normal peripheral position with acute skeletal muscular infarction, and infiltration of accumulated inflammatory cells. Atorvastatin has been revealed to have several adverse effects on the skeletal muscle and the nerve supply. Based on the data in the current study, it is evident that atorvastatin administration for less than two months resulted in some sorts of myotoxic structural changes and apoptosis as evident by deformity and lack of striation degeneration of nuclei, as well as splitting of the muscle fibers in the adult male rats' skeletal muscle.

Entities:  

Keywords:  Hyperlipidemia; Low-density lipoprotein cholesterol; Myofibers

Mesh:

Substances:

Year:  2022        PMID: 35891762      PMCID: PMC9288636          DOI: 10.22092/ARI.2021.356683.1895

Source DB:  PubMed          Journal:  Arch Razi Inst        ISSN: 0365-3439


  15 in total

Review 1.  Update on statins: 2003.

Authors:  Carl J Vaughan; Antonio M Gotto
Journal:  Circulation       Date:  2004-08-17       Impact factor: 29.690

Review 2.  [Statin intolerance and associated muscular dysfunctions].

Authors:  Antoine Boulanger-Piette; Jean Bergeron; Joël Desgreniers; Michèle Côté-Levesque; Dominic Brassard; Denis R Joanisse; Jérôme Frenette
Journal:  Med Sci (Paris)       Date:  2015-12-16       Impact factor: 0.818

Review 3.  Statin-induced myopathies.

Authors:  Michał Tomaszewski; Karolina M Stępień; Joanna Tomaszewska; Stanisław J Czuczwar
Journal:  Pharmacol Rep       Date:  2011       Impact factor: 3.024

Review 4.  Statin-induced myopathy: the two faces of Janus.

Authors:  Rohit Arora; Max Liebo; Frank Maldonado
Journal:  J Cardiovasc Pharmacol Ther       Date:  2006-06       Impact factor: 2.457

5.  Inflammatory Pathways Regulated by Tumor Necrosis Receptor-Associated Factor 1 Protect From Metabolic Consequences in Diet-Induced Obesity.

Authors:  Nathaly Anto Michel; Christian Colberg; Konrad Buscher; Björn Sommer; Akula Bala Pramod; Erik Ehinger; Bianca Dufner; Natalie Hoppe; Katharina Pfeiffer; Timoteo Marchini; Florian Willecke; Peter Stachon; Ingo Hilgendorf; Timo Heidt; Constantin von Zur Muhlen; Dominik von Elverfeldt; Dietmar Pfeifer; Roland Schüle; Ulrich Kintscher; Sebastian Brachs; Klaus Ley; Christoph Bode; Andreas Zirlik; Dennis Wolf
Journal:  Circ Res       Date:  2018-01-22       Impact factor: 17.367

6.  Scaling of muscle architecture and fiber types in the rat hindlimb.

Authors:  Carolyn M Eng; Laura H Smallwood; Maria Pia Rainiero; Michele Lahey; Samuel R Ward; Richard L Lieber
Journal:  J Exp Biol       Date:  2008-07       Impact factor: 3.312

7.  Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats.

Authors:  William H Schaefer; Jeffery W Lawrence; Amy F Loughlin; Dana A Stoffregen; Lori A Mixson; Dennis C Dean; Conrad E Raab; Nathan X Yu; George R Lankas; Clay B Frederick
Journal:  Toxicol Appl Pharmacol       Date:  2004-01-01       Impact factor: 4.219

8.  Genetic Deficiency of TRAF5 Promotes Adipose Tissue Inflammation and Aggravates Diet-Induced Obesity in Mice.

Authors:  Mark Colin Gissler; Nathaly Anto-Michel; Jan Pennig; Philipp Scherrer; Xiaowei Li; Timoteo Marchini; Katharina Pfeiffer; Carmen Härdtner; Tijani Abogunloko; Timothy Mwinyella; Lucia Sol Mitre; Lisa Spiga; Christoph Koentges; Christian Smolka; Dominik von Elverfeldt; Natalie Hoppe; Peter Stachon; Bianca Dufner; Timo Heidt; Sven Piepenburg; Ingo Hilgendorf; Jan-Inge Bjune; Simon N Dankel; Gunnar Mellgren; Gabriel Seifert; Steffen U Eisenhardt; Heiko Bugger; Constantin von Zur Muhlen; Christoph Bode; Andreas Zirlik; Dennis Wolf; Florian Willecke
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-08-05       Impact factor: 8.311

Review 9.  Approach to asymptomatic creatine kinase elevation.

Authors:  Siamak Moghadam-Kia; Chester V Oddis; Rohit Aggarwal
Journal:  Cleve Clin J Med       Date:  2016-01       Impact factor: 2.321

10.  Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England.

Authors:  Peter Ueda; Thomas Wai-Chun Lung; Yuan Lu; Joshua A Salomon; Kazem Rahimi; Philip Clarke; Goodarz Danaei
Journal:  PLoS One       Date:  2018-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.